-
1
-
-
54949143968
-
Alemtuzumab vs. Interferon beta-1a in early multiple sclerosis
-
Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359: 1786-1801.
-
(2008)
N Engl J Med
, vol.359
, pp. 1786-1801
-
-
Coles, A.J.1
Compston, D.A.2
Selmaj, K.W.3
-
2
-
-
84869492471
-
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial
-
Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380: 1819-1828.
-
(2012)
Lancet
, vol.380
, pp. 1819-1828
-
-
Cohen, J.A.1
Coles, A.J.2
Arnold, D.L.3
-
3
-
-
84869507357
-
Alemtuzumab for patients with relapsing multiple sclerosis after diseasemodifying therapy: A randomised controlled phase 3 trial
-
Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after diseasemodifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380: 1829-1839.
-
(2012)
Lancet
, vol.380
, pp. 1829-1839
-
-
Coles, A.J.1
Twyman, C.L.2
Arnold, D.L.3
-
5
-
-
84857055778
-
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis
-
Hill-Cawthorne GA, Button T, Tuohy O, et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2012; 83: 298-304.
-
(2012)
J Neurol Neurosurg Psychiatry
, vol.83
, pp. 298-304
-
-
Hill-Cawthorne, G.A.1
Button, T.2
Tuohy, O.3
-
6
-
-
84860780657
-
Alemtuzumab more effective than interferon-1a at 5-year follow-up of camms223 clinical trial
-
Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012;78: 1069-1078.
-
(2012)
Neurology
, vol.78
, pp. 1069-1078
-
-
Coles, A.J.1
Fox, E.2
Vladic, A.3
-
7
-
-
84890285333
-
Human autoimmunity after lymphocyte depletion is caused by homeostatic t-cell proliferation
-
Jones JL, Thompson SA, Loh P, et al. Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. Proc Natl Acad Sci USA 2013;110: 20200-20205.
-
(2013)
Proc Natl Acad Sci USA
, vol.110
, pp. 20200-20205
-
-
Jones, J.L.1
Thompson, S.A.2
Loh, P.3
-
8
-
-
84873690365
-
Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis
-
Cossburn MD, Harding K, Ingram G, et al. Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis. Neurology 2013;80: 55-61.
-
(2013)
Neurology
, vol.80
, pp. 55-61
-
-
Cossburn, M.D.1
Harding, K.2
Ingram, G.3
-
10
-
-
84863304598
-
-
R Core Team. Vienna Austria: R Foundation For Statistical Computing; 2013. Available at. Accessed August 16
-
R Core Team. R: A Language and environment for statistical computing [computer program]. Vienna, Austria: R Foundation for Statistical Computing; 2013. Available at: http://www.R-project.org/. Accessed August 16, 2013.
-
(2013)
R: A Language And Environment For Statistical Computing [Computer Program]
-
-
-
11
-
-
31544467633
-
The window of therapeutic opportunity in multiple sclerosis: Evidence from monoclonal antibody therapy
-
Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006;253: 98-108.
-
(2006)
J Neurol
, vol.253
, pp. 98-108
-
-
Coles, A.J.1
Cox, A.2
Le Page, E.3
-
12
-
-
0032882173
-
Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
-
Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999;46: 296-304.
-
(1999)
Ann Neurol
, vol.46
, pp. 296-304
-
-
Coles, A.J.1
Wing, M.G.2
Molyneux, P.3
-
13
-
-
0030880011
-
Treatment of multiple sclerosis with the monoclonal anti-cd4 antibody cm-T412: Results of a randomized, double-blind, placebo-controlled, mr-monitored phase ii trial
-
van Oosten BW, Hodgkinson S, Barkhof F, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 1997;49: 351-357.
-
(1997)
Neurology
, vol.49
, pp. 351-357
-
-
Van Oosten, B.W.1
Hodgkinson, S.2
Barkhof, F.3
-
14
-
-
27944439639
-
Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis
-
Cox AL, Thompson SA, Jones JL, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 2005;35: 3332-3342.
-
(2005)
Eur J Immunol
, vol.35
, pp. 3332-3342
-
-
Cox, A.L.1
Thompson, S.A.2
Jones, J.L.3
|